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Systemic lupus erythematosus (SLE) is a complex auto-immune disorder which involves various facets of the immune system. In
addition to autoantibody production and immune complex deposition, emerging evidences suggest that cytokines may act as key
players in the immunopathogenesis of SLE. These cytokines assume a critical role in the differentiation, maturation and activation
of cells and also participate in the local inflammatory processes that mediate tissue insults in SLE. Certain cytokines such as the
IL-6, IL-10, IL-17, BLys, type I interferons (IFN) and tumor necrosis factor-α (TNF-α) are closely linked to pathogenesis of SLE.
The delineation of the role played by these cytokines not only fosters our understanding of this disease but also provides a sound
rationale for various therapeutic approaches. In this context, this review focuses on selected cytokines which exert significant effect
in the pathogenesis of SLE and their possible clinical applications.
1. Introduction
Systemic lupus erythematosus (SLE) is an intriguing auto-
immune disease which constitutes a complex interaction
between the innate and adaptive immune system. Conven-
tional belief has cornered SLE to be primarily a disease of
autoantibodies and immune complex deposition. However,
mounting evidence has implied that cytokines are also key
players in the pathogenesis. Cytokines are soluble factors
which play a pivotal role in the differentiation, maturation,
and activation of various immune cells. They are not
only involved in immune dysregulation of SLE, but also
in the local inflammatory response which ultimately leads
to tissue injury. The knowledge of cytokines not only
provides new insight into pathogenesis of SLE, but also
sheds light on various clinical applications. Certain cytokines
may serve as biomarkers to monitor disease activity and
predict disease severity. In addition, the manipulation of
these cytokines may become potential therapeutic targets for
the treatment of SLE. In this context, cytokines which have
significant implications in the pathogenesis of SLE will be
reviewed.
2. Interleukin 6 (IL-6)
IL-6 is a pleiotropic cytokine synthesized predominantly
by monocytes, fibroblasts, and endothelial cells, although
its secretion may also be found in T- and B-lymphocytes
[1]. Its production is triggered by IL-1, IL-2, and TNF-α
but dampened by IL-4, IL-10, and IL-13. One of the
most important effects of IL-6 is to induce the maturation
of B lymphocytes into plasma cells and augment the
immunoglobulin secretion [2, 3]. Other actions include
the up-regulation of IL-2 and its receptor expression,
stimulation of platelet production from megakaryocytes,
differentiation of macrophage and osteoclast as well as the
production of acute phase reactants [3]. IL-6 binds to
the IL-6 receptors which belong to the type 1 cytokine
receptor superfamily that consists of two subunits, namely
the IL-6 R and the gp 130. The interaction between IL-6
and its receptor results in the dimerization of gp130,
activation of JAK1 and subsequent tyrosine phosphorylation
of gp130 [3]. The pivotal role of IL-6 in the pathogenesis
of SLE had been supported by both murine and human
experiments.
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2.1. Role of IL-6 in Lupus Mice Models. In MRL/lpr mice,
there exists an age-related elevation of serum IL-6 levels,
soluble IL6-R and aberrant expression of the IL-6 R [4,
5]. It should be highlighted that no other lymphokine
studies have been shown to be capable of directly inducing
the IgG anti-DNA antibodies. Exogenous administration of
recombinant human IL-6 accelerated glomerulonephritis in
NZB/W mice [6]. In IL-6 deficient MRL/lpr mice, there
was significant reduction of infiltrating macrophages in the
kidney, a decrease in renal IgG and C3 deposition, and
a diminution of CD4+ and CD8+ lymphocytes with the
absence of IL-6 [7]. The renal parenchymal expression of
adhesion molecule VCAM-1 was also found to be down-
regulated in MRL-Fas(lpr) IL-6−/− compared to IL-6-intact
mice [7]. These data support the notion that IL-6 is a strong
promoter of lupus nephritis and may be a promising new
therapeutic target in the treatment of human lupus nephritis.
In fact, IL-6 blockade modulated the age-related raise in
anti-ds DNA levels, retarded proteinuria and significantly
improved mortality in NZB/W mice [8, 9]. In B6.Sle1.Yaa
mice, IL-6 levels were elevated and the increase was coupled
with the loss of CD19+ B cells and more primitive B-
lymphoid progenitors in bone marrow [10]. Stimulation by
IL-6 prompted these uncommitted progenitor cells to express
transcription factors which inhibited lymphopoiesis and
promoted myelopoiesis in SLE. Another mechanism of how
IL-6 may affect the B cell survival is via the recombination-
activation gene (Rag) machinery which are crucial for the
revision of rearranged immunoglobulin V (D) J genes. IL-
6 favors the expression of Rags and hence facilitates the
rescue of autoreactive B cells from apoptosis [11]. In Jun
B(Delaep) mice, the development of SLE phenotype was
linked to increased epidermal IL-6 secretion and intercrosses
with IL-6 deficient mice could rescue the SLE phenotype
[12]. These studies suggest a possible role of IL-6 in the
generation of autoantibodies and the development of various
clinical manifestations in animal models.
2.2. Role of IL-6 in Human SLE. In human lupus patients,
accentuated IL-6 levels correlated with the disease activity
and anti-DNA levels [13, 14]. Lymphoblastoid cells isolated
from lupus subjects expressed high levels of IL-6 and IL-6
antagonism resulted in reduction of anti-ds DNA in vitro
[15]. In contrast to healthy subjects, B lymphocytes from
lupus patients spontaneously generate heightened quantity
of immunoglobulins (Ig). IL-6 blockade significantly abol-
ished this spontaneous immunoglobulin synthesis which
was restored with exogenous IL-6 administration [14]. It
had been shown that B-lymphocytes from lupus patients
secreted anti-ds DNA spontaneously and this autoantibody
production ex vivo was predominantly caused by low density
B lymphocytes [16]. It is worthwhile to note that IL-6 can
facilitate these low density B cells from active lupus subjects
to differentiate directly into Ig-secreting cells [16]. CD5
expression suppressed BCR signaling in SLE B cells and
IL-6 down-regulated CD5 expression via DNA methylation
and hence promoted the activation and expansion of auto-
reactive B cells in SLE patients [17]. Apart from its systemic
effects, IL-6 was shown to have a particularly close link with
the renal manifestation of SLE. Several studies demonstrated
elevated urinary IL-6 excretion in patients with active lupus
nephritis (WHO Class III/IV lupus nephritis) who also had
high titers of anti-ds DNA antibodies [18, 19]. The urinary
level of IL-6 in patients with active lupus nephritis was
higher than that in patients with quiescent renal disease
[20]. Moreover, there was enhanced in situ expression of
IL-6 along the glomeruli and tubules in lupus nephritis
kidneys [21]. Apart from the kidneys, neuropsychiatric
manifestation was associated with an excessive IL-6 levels in
the cerebrospinal fluid of lupus patients [22]. These findings
of raised IL-6 in local tissues have suggested the pathogenetic
role of IL-6 in mediating local inflammation and tissue
insults. IL-6 and its receptors may be useful biomarkers
to monitor disease activity and treatment response. IL-6
release from PBMC was associated with disease activity and
treatment response in lupus nephritis patients [23]. Other
studies have also revealed an increased expression of IL-
6 agonistic receptor gp130 on peripheral lymphocytes in
SLE patients and its level correlated with the disease activity
[24]. The success of IL-6 antagonism in murine models has
prompted research into the therapeutic application of IL-6
in human lupus. Tocilizumab (Anti-IL6 R antagonist) when
used in mild to moderate lupus patient has demonstrated
preliminary success and good tolerability in phase I trials
[25].
3. Interleukin 10 (IL-10)
IL-10 is a cytokine produced mainly by monocytes and
lymphocytes. It impedes the activation of antigen pre-
senting cells (APC), down-regulates the expression of co-
stimulatory molecules and, thereby, blunts T cell activation
and TNF-α secretion [26]. IL-10 boosts B cell proliferation
and immunoglobulin class switching resulting in enhanced
antibody secretion with the capacity to enter extravascular
compartments and promote inflammation in SLE. Several
stimuli, including anti-ds DNA antibodies and immune
complexes when bound to FcγRII, are potent triggers of IL-
10 [27, 28]. Prominent staining of IL-10 in intra-renal cells
was detected in kidneys of lupus patients [29], although the
data suggested that the IFNγ/IL-10 ratio is of more clinical
relevance. Elevated IFNγ/IL-10 ratio was observed in active
class IV lupus nephritis, while class V nephritis may behave
oppositely in this regard [29]. Apparently, the increased IL-10
was of pathogenic bearing in NZB/W mice where the effects
of IL-10 were largely opposite to those of TNF-α [30]. In fact,
anti-IL10 therapy led to increased TNF-α and its beneficial
effects were abrogated when TNF-α was blocked [30]. On the
other hand, IL-10 appeared to play a role in the regulatory T
cell commitment and action [31], which might be beneficial
in SLE. The observed down-regulation of T cell activation
in peripheral blood mononuclear cells from SLE patients
was consistent with such effects [32]. In animal models of
lupus nephritis, anti-IL 10 blockade offered some benefits
in limiting renal damage [33]. Preliminary data have shown
that anti-IL-10 monoclonal antibody improved cutaneous
lesions, joint symptoms, and SLEDAI in lupus patients
[34].
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4. Interleukin 17 (IL-17)
IL-17 is a type I transmembrane protein isolated initially
from a rodent CD4+ T cell cDNA library [35]. It is a
potent pro-inflammatory cytokine produced by activated T
lymphocytes, with the “Th17 cells” being the most vibrant
producer. These Th17 cells are in fact a subset of CD4+
T lymphocytes named after its hallmark cytokine IL-17.
Th17 cells are regarded as a distinct T helper cell subset
because they originate from naı¨ve T cells and only exhibit
a characteristic cytokine release profile when appropriately
primed by exclusive transcription factors. There are a total
of six family members (IL-17 A to F) and five receptors
(IL-17R A to E) in the IL-17 family [36]. IL-17 has great
potency to recruit monocytes and neutrophils, facilitate T
cell infiltration, and up-regulate adhesion molecule expres-
sions [37, 38]. Several important cytokines including IL-
6, IL-21, and IL-23 are in intimate association with IL-17.
The combination of IL-6 and transforming growth factor
(TGF)β was shown to induce the differentiation of murine
naı¨ve T cells into Th17 cells [39, 40]. Conversely, IL-6
deficient mice demonstrated defective Th17 differentiation
[39]. These observations implied that the presence of an
inflammatory signal is required to transform the naı¨ve T
cells to become pro-inflammatory. IL-21 is another factor
which exerts a strong influence for Th-17 differentiation.
Unlike IL-6, IL-21 is produced by the Th17 cells as well as the
T-follicular helper cells but not by antigen presenting cells
and, hence, being postulated to act as an auto-amplifier of
Th17 response [40]. Moreover, it is important to note the
effect of IL-23 on a pathogenic Th17 response in naı¨ve wild-
type mice upon T cell adoptive transfer [41]. In addition,
IL-23 enhances IL-17 production by memory T cells [42].
Taken together, these findings suggest the presence of a novel
T helper functional axis (IL-23/IL-17 axis) which may be
important in the pathogenesis of autoimmune disorders.
Although naı¨ve CD4+ T cells can differentiate into Th1, Th2,
or Th17 effector subsets, the cytokine milieu characteristic of
SLE patients (IL-2 poor but IL-6 and IL-21 rich) favors Th17
expansion. Th17 cells can also serve as an independent T
helper effector cell subset promoting inflammation through
cytokine secretion. The signature cytokines secreted by the
Th17 cells include IL-17A, IL-17F, IL-21, and IL-22 [43].
This array of cytokines can stimulate B lymphocytes, and
set off local inflammation and tissue injury leading to the
pathogenesis of SLE. Evidences supporting the role of IL-17
in SLE pathogenesis are found in both animal and human
lupus.
4.1. Role of IL-17 in Lupus Mice Models. In MRL/lpr mice,
enhanced IL-17 mediated tissue injury was observed after
ischemic reperfusion of the gut [44]. In IL-12R deficient
BXD2 mice, there was diminished splenic germinal centre
formation as well as lower anti-DNA and antihistone anti-
bodies levels [45]. Furthermore, splenocytes from SNF1 mice
secreted higher level of IL-17 than non-autoimmune B6 mice
[46]. CD3+CD4−CD8− T cells from MRL/lpr mice produced
copious IL-17 and the expression of IL-17 and IL-23 recep-
tors in the lymphocytes from these mice increased as the
disease progressed [47]. These lymphoid cells from MRL/lpr
mice, after treatment with IL-23 in vitro and transferred to
non-autoimmune species, can induce nephritis [47]. These
data indicate that an aberrantly active IL-23/IL-17 axis is
responsible for the development of nephritis in lupus-prone
mice.
4.2. Role of IL-17 in Human SLE. In human subjects, SLE
patients have raised serum levels of IL-17 and IL-23 and the
plasma level of IL-17 correlates with disease activity [48].
Recent data have suggested that a significant portion of IL-17
in SLE patients is contributed by the TCR-αβ+CD4−CD8−
T lymphocytes [49]. These CR-αβ+CD4−CD8− T cells and
Th17 cells are also found in renal biopsies from lupus
nephritis patients, supporting their pathogenic role in renal
lupus [49].
5. B-Lymphocytes Stimulators (BLys)
B lymphocyte stimulator (BLys) is a member of the tumor
necrosis factor ligand family. Being a type-II transmembrane
protein, it is cleaved at the cell surface by furin protease that
results in the release of a soluble, biologically active molecule
[50]. Expression of BLys is highly confined to myeloid
lineage cells (e.g., monocytes, macrophages, dendritic cells
and activated neutrophils) and its release is upregulated
by interferon-γ and IL-10 [50]. BLys couples intensely to
B lymphocytes and is a vital factor for B lymphocyte
proliferation and immunoglobulin secretion as suggested by
recent data [51]. In BLys-deficient mice, there is significant
shrinkage in numbers of mature B cells, reduced baseline
serum immunoglobulin levels and impaired immunoglobu-
lin response to T cell dependent and independent antigens
[52]. Three types of BLys receptor are found, namely,
BAFFR, BCMA, and TACI receptors. BLys can bind to these
three receptors on B cells, whereas a proliferation-inducing
ligand (APRIL) can only engage to TACI and BCMA [53].
Among these three receptors, the BAFFR receptor is the
most important one mediating most of the BLys effects.
Mice deficient in BCMA and TACI receptors exhibit no
discernible phenotypic or functional abnormalities [52, 54].
In contrast, A/WySnJ mice (which bear a mutated baffr gene)
display a reduction in mature B cell numbers and antibody
level reminiscent of BLys-deficient mice [55]. BLys-triggered
intracellular events are complex mainly mediating through
the interaction of BLys receptors and several TNF receptor
associated factors (TRAFs). Docking of BLys with its recep-
tors activates phospholipase C-γ2 [56] and subsequently the
NF-κB pathways [57]. This results in the inhibition of B cell
apoptosis and hence prolonged B lymphocyte survival.
5.1. Role of BLys in Lupus Mice Models. In murine mod-
els, there are several distinct observations which suggest
the contribution of BLys to the pathogenesis of SLE. In
BLys transgenic mice (BLys-Tg mice), overproduction of
BLys not only leads to polyclonal hypergammaglobuline-
mia but also elevated titres of multiple autoantibodies
(including anti-ds DNA), circulating immune complexes and
renal immunoglobulin deposition [58]. These mice develop
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Figure 1: Schematic diagram to show the complex interaction between various immune cells and cytokines which lead to the pathogenesis
of SLE.
autoimmune disorders similar to SLE and Sjogren syndrome
[58]. In SLE-prone mice such as the (NZB/W) F1 mice and
MRL-lpr/lpr mice, raised levels of BLys are detected at the
onset of disease [59]. Treatment of NZB/WF1 mice with
soluble TACI-Ig fusion protein prevented the development
of proteinuria and prolonged the survival of the animals
[59]. These findings highlight the involvement of BLys and
its receptors in the development of SLE and indirectly suggest
TACI-Ig as a promising treatment for human autoimmune
disease. Furthermore, mice treated with exogenous BLys
showed increased numbers of antichromatin B cells and
augmented production of anti-ds DNA antibodies [60].
Deletion of either BLys or BR3 severely impaired B cell
development beyond the transitional developmental stages
[52, 55, 59, 61]. T-cell-deficient BAFF transgenic (Tg) mice
developed SLE similar to T-cell-sufficient BAFF Tg mice, and
these features were associated with innate activation of B cells
and release of pro-inflammatory autoantibodies. These data
suggest that a dysregulated innate activation of B cells alone
can drive disease independently of the T cells [62].
5.2. Role of BLys in Human SLE. Circulating level of BLys
was raised in human lupus patients and the level correlated
with the anti-ds DNA level [63]. In a survey which measured
the serum BLys level and disease activities, healthy controls
uniformly displayed a normal serum BLys level over time,
whereas escalated BLys level was observed in SLE patients
(persistent elevation in 25% and intermittent elevation in
another 25% of patients) [64]. Although the aforementioned
observations make BLys a promising therapeutic target, data
regarding BLys-targeted therapy are not as encouraging as
expected in lupus patients. In a phase I trial of Belimumab
(a fully humanized monoclonal antibody (IgG1) that binds
to soluble BLys and hence inhibits its binding to TACI,
BCMA, and BAFFR), there was no significant improvement
in disease activity despite a reduction in the CD20+ B
cells [65]. Trial of atacicept (a fusion protein against the
TACI receptor) showed a trend toward clinical improvement
in moderate SLE [66], yet phase II trial of this drug in
lupus nephritis was suspended due to high risk of severe
infections.
6. Type I Interferons (Type I IFN)
Interferons (IFN) are proteins with the capacity to suppress
viral replications: the types I IFNs are regarded the most
important ones in human lupus. Viral DNA and RNA are
classical triggers of type I IFN and the signals are mediated
via the Toll-like receptors (TLR) or the retinoic acid-
inducible gene I (RIG-I) like receptors [67]. Double-stranded
RNA stimulates IFN release via TLR3 while single stranded
RNA induces IFN via TLR7/8 and the cytosine-phosphate-
guanine (CpG) rich DNA via TLR9 [68]. Type I IFNs are
produced by all leucocytes with plasmacytoid dendritic cells
(PDC) as the most active secretor in response to TLR7 or
TLR9 activation [69]. Several mechanisms of how IFNs may
contribute to the pathogenesis of SLE have been proposed.
Immune complexes generated from autoantibodies and
autoantigens lead to dendritic cell activation and hence
enhanced antigen presentation and increased IFN secretion
[70]. IFNs can increase the expression of autoantigen such as
Ro52 [71] and also the release of autoantigens by translo-
cation of Ro52 to the nucleus with subsequent induction
of apoptosis [72]. Other actions include the promotion of
dendritic cell maturation and upregulation of cell surface
molecules (MHC Class I and II, costimulatory molecules)
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Table 1: Important cytokines in SLE: the major secreting cells and possible clinical applications.
Cytokines Major secreting cells Possible Clinical applications
IL-6
Monocytes
(i) Tocilizumab (Anti-IL6R Ab) showed good efficacy and tolerability in phase 1 trial
for mild to moderate lupus [25]Fibroblasts
Endothelial cells
IL-10
Monocytes (ii) Anti-IL10 monoclonal antibody improve cutaneous lesions, joint symptoms and
SLEDAI in lupus patients [34]Lymphocytes
IL-17
Lymphocytes
(Th-17 subset)
(iii) Still under investigation
BLys
Monocytes (iv) Belimumab (monoclonal Ab against soluble BLys) showed reduction in CD20+ B
cells but no significant improvement in disease activity [65]Macrophages
Dendritic cells (v) Atacicept (fusion protein against TACI receptor) showed clinical improvement for
moderate lupus but phase II trial suspended due to high infective riskActivated neutrophils
Type 1 Interferon
(IFN)
Plasmacytoid dendritic
cells (PDC)
(vi) IFN regulated chemokines used in monitoring of disease activity and organ
damage [90, 91]
(vii) Anti-IFN monoclonal antibody showed improvement in disease activity in phase
I trial [92]
TNF-alpha
Macrophages (viii) Infliximab (Anti-TNFα) improved joint symptoms and proteinuria in lupus
patients with moderate activity [103]Dendritic cells
(ix) Infliximab (Anti-TNFα) resulted in sustained remission in Class IV lupus
nephritis patients who failed to achieve remission with steroid/MMF/cyclosporine
[104]
[73]. These effects orchestrate the development of Th1
response. In addition, type I IFNs also enhance antibody
production and class switching, decrease the selectivity of
B cells for CpG-rich DNA, and permit stimulation by even
non-CpG DNA [74, 75]. Elevation of type I IFN in lupus
patients was one of the first described cytokine abnormalities
in autoimmune diseases. The association of IFN levels and
disease activity, anti-ds DNA levels, and clinical manifesta-
tions supports the role of IFN in SLE pathogenesis [76].
Although PDC population is lower in the peripheral blood
of lupus patients, they are found in the dermal lesions
and are responsible for the continuous IFN release [77].
PDC can also accumulate in active lupus nephritis and the
migration of these cells to the glomeruli is thought to be
influenced by IL-18 [78]. Findings from experimental lupus
model suggested that IFN drive the lupus nephritis and
end organ damage [79]. Autoantibodies with the ability to
form very potent interferogenic immune complexes together
with RNA-containing autoantigens were detected in the
cerebrospinal fluid of patients with cerebral lupus [80]. Gene
expression profiling showed that SLE patients expressed IFN
inducible genes in PBMC and the expression correlated
with disease activities [71]. These findings demonstrate that
raised IFN levels are capable of inducing alterations in gene
expression in active lupus patients and support the notion
that IFNs play an important pathogenic role in SLE. In
the contrary, deficiency of the IFN α/β receptor resulted in
attenuation of autoantibody production and amelioration of
disease in NZB/W mice [81]. This again provides indirect
evidence that IFNs exert a significant impact on SLE.
Moreover, patients receiving anti-IFN therapy for other
disease may develop autoantibodies and SLE-like syndrome
[82]. The causal role of IFN in SLE is further supported
by genetic studies. Transcription factor IRF5 was the first
identified gene directly involved in IFN production and was
associated with increased risk of lupus [83]. Lupus patients
with a risk haplotype of IRF5 had higher serum IFN activity
when compared to patients lacking this risk genotype and the
effect was most prominent in patients with autoantibodies
against either RNA-binding proteins or double-stranded
DNA [84]. Another example is the signal transducer and
activator of transcription 4 (STAT4) which interacts with the
cytoplasmic part of the IFNAR and variants of STAT4 have
been shown to be strongly associated with lupus [85]. A link
between the IFN response and SLE had also been established
for patients with polymorphism of Jak TYK2 [86]. Clinical
applications of the IFN include the use as a biomarker as
well as a therapeutic target. Healthy first degree relatives of
lupus patients have increased serum IFN activity [87] and
the levels are more pronounced in younger individuals [88].
A combination of risk alleles in the type I signaling pathway
(e.g., STAT4 and IRF5) may imply an additive risk of disease
[89]. It can be inferred that the use of genetic mapping may
help predicting the development and severity of disease in the
future. IFN regulated chemokines may also be employed to
monitor disease activity and organ damage [90, 91]. A phase
I clinic trial of anti-IFN monoclonal antibodies showed a
dose-dependent inhibition of type I IFN-inducible genes in
both the peripheral blood and skin biopsies in parallel with
reduction in disease activity [92].
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7. Tumor Necrosis Factor-α (TNF-α)
Tumor necrosis factor-alpha (TNF-α) is expressed as a trimer
on cell surface and in soluble form after the activation of
macrophages and dendritic cells. The significance of TNF-α
in the pathogenesis of SLE remains controversial since it has
been depicted as both protective and detrimental in different
murine models.
7.1. Role of TNFα in Lupus Mice Models. Previous findings
in NZB/W mice showed diminished production of TNF-α
[93]. In NZB/W mice, TNF-α deficiency is an important
trigger for lupus-like autoimmunity. While TNF-α deficient
NZB/W mice develop severe disease manifestations, TNF-α
competent NZB/W mice only show modest lupus activity
[94]. In contrast, TNF-α concentration was high in both sera
and renal tissue of MRL/lpr lupus mice and the levels of
TNF-α correlated with the severity of kidney disease [95].
Moreover, even in NZB/W mice, renal expression of TNF-
α is elevated in conjunction with kidney inflammation [96].
In MRL/lpr mice, anti-TNFα therapy offered improvement
of joint and lung manifestations in these animal models
[97, 98].
7.2. Role of TNF-α in Human SLE. There is substantial
evidence to show that TNF-α may play a similar pro-
inflammatory role in human SLE. Serum levels of TNF-α
in active SLE patients closely correlated with disease activity
[99] and abundant TNF-α expression was demonstrated
in lupus nephritis kidneys [23]. Nevertheless, conflicting
results were observed in patients with other autoimmune
diseases receiving anti-TNF-α therapy [100, 101]. These
patients developed antinuclear factors, anti-ds DNA and
anticardiolipin antibodies as well as a lupus-like syndrome.
Yet these symptoms and autoantibodies resolved following
discontinuation of TNF-α blocking therapy. Given the
findings of elevated serum TNF-α in active SLE and over-
expression of TNF-α in active lupus nephritis [23, 102],
TNF-α antagonism still appears to be an attractive option
for the treatment of active lupus disease. However, evidence
for therapeutic efficacy of TNF-α blockade in SLE is still
limited [103, 104] and larger prospective studies are needed
to evaluate their effectiveness and side effects profile.
8. Concluding Remarks
This review has discussed an array of information on a
possible pathogenic link between the various cytokines and
SLE (Figure 1). There are still many facets of inflammatory
cascades elicited by these cytokines to be elucidated. A
more in-depth understanding of these cytokines may be of
clinical significance in the context of devising biomarkers or
therapeutic agents (Table 1). Most of the recent trials have
addressed the use of cytokinetargeted agents in the induction
phase of severe disease manifestation or in refractory cases.
These new therapies may offer an advantage to achieve rapid
disease control and to minimize the corticosteroid usage.
However, the role of these anticytokine treatments in the
maintenance phase still remains undefined. One must also
appreciate that interactions between the cytokine milieus
are complex and the attenuation of one cytokine may have
potentiated more profound effects than expected. The long-
term use of these cytokines as a therapeutic target may
appear attractive, yet one must be alerted to the possible
complications such as infection and malignancy.
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